Mounjaro®

Branded GLP-1. Weekly self-injection pen (Eli Lilly)

FDA-approved dual GIP and GLP-1 receptor agonist for type 2 diabetes.

Dosing: Set by your prescriber and adjusted over time based on how you respond.

Best for: Patients with type 2 diabetes seeking the dual-incretin mechanism of tirzepatide.

Key points

• FDA-approved for type 2 diabetes
• Same active ingredient as Zepbound® at diabetes-focused dosing
• Managed by a HELiXVi clinician

Considerations

• Weight-loss use may be off-label depending on indication
• Prescription-only, insurance coverage varies

Prescription treatment requires an online consultation with a licensed HELiXVi clinician. Individual results vary.

Start your free consultation right now

No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.

See the full weight loss program